Angel Biotech (LON:ABH) (ABH 0.5p / £13.40m)*
AIM listed biopharmaceutical contract manufacturer last week announced the signing of a 5 year pricing agreement with Materia Medica Holding, a leading pharmaceutical company in Russia. Under the agreement, contract prices between the companies are agreed over the next 5 years. It is Materia Medica's intention to sign a minimum of three further GMP manufacturing contracts with Angel over the period with a potential cumulative value of over £4.5m.
Last month saw a run of good announcements for Angel. First a positive update on trading for the year ended 31 December 2010, with over £5.3m of new contracts signed in 2010, and the Company already having signed 81 per cent of revenues forecast for 2011. Second a placing raising £1.94m was announced. And third, right at the end of January, the Company announced that it had signed a new contract with Pathfinder Cell Therapy, a company based in Massachusetts, and focused on the development of its Pathfinder Cell Platform in regenerative cell therapies. The contract is to provide pre-GMP services for this novel cell therapy. It is good to see Angel taking advantage of this market opening up in the US and fully imagine under Obama to see Angel benefitting from a new political openness to stem cell therapies and other advanced biologics.
Angel is in the process of increasing its manufacturing capacity as a direct response to the continuing demand for Angel’s products and to help capitalise on growth in the EU and US market. The recent placing should help with that strategy and great to see the announcement of new contracts underpinning this stellar growth.
Ant (LON:ANTP) (ANTP 32p / £7.77m)
Good news for ANT. Humax, one of the world’s largest manufacturers of set top boxes, has launched its new TV portal which uses ANT’s Galio platform. Humax have released updates to all HDR-FOX T2 Freeview HD Set Top boxes across the UK, thereby resulting in a wider reach of ANT related products. Users are now afforded the luxury of having access to content providers such as Flickr, BBC iPlayer, and in the near future, Sky Player. User experiences will provide a clearer indication as to whether the product will gain traction with the wider market, though Humax’s willingness to roll out the product in what is…
